Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminocamptothecin in advanced ovarian cancer
NCT00002671Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Dec 1995
- Primary completion
- Feb 2001
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 9-aminocamptothecin in ovarian cancer, sponsored by NYU Langone Health. Primary endpoint: Objective Response Rate. Started Dec 1995; status: completed.
02
Drugs
9-aminocamptothecin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00002671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002671.